Evidence map›Paper›PMID 42464078›Full record

SynthesisWorld journal of surgical oncology2026

Conversion hepatectomy and survival in initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis with quantitative bias analysis.

Wenguang Zhao, Xialin Zhang, Ao Zhong, Chenxi Jiang, Ran Cui, Xinlin Yu, Sheng Lin

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenguang Zhao *Department of Oncology, Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District, Luzhou, Sichuan, 646000, China.
Xialin Zhang *Department of Oncology, Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District, Luzhou, Sichuan, 646000, China.
Ao ZhongDepartment of Oncology, Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District, Luzhou, Sichuan, 646000, China.
Chenxi JiangDepartment of Oncology, Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District, Luzhou, Sichuan, 646000, China.
Ran CuiDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Neijiang, Neijiang, Sichuan, 641000, China.
Xinlin YuDepartment of Oncology, Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District, Luzhou, Sichuan, 646000, China.
Sheng LinDepartment of Oncology, Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District, Luzhou, Sichuan, 646000, China. lslinsheng@163.com.ORCID http://orcid.org/0000-0002-8133-4082

Funding

Sichuan Medical Association 2024 Special Research Project SC202401Sichuan Province Centralised Guidance for Local Science and Technology Development Project 2024ZYD0334The 2025 Medical Science and Technology Projects of Sichuan Provincial Health Commission 25QNMP080The 2025 research project from the Sichuan Provincial Administration of Traditional Chinese Medicine 25MSZX347Wu Jieping Medical Foundation 2024 Special Research Project on Tumour Immunity 320.6750.2024-6-129
6 · The paper itself

Abstract

backgroundConversion hepatectomy has become feasible for selected patients with initially unresectable hepatocellular carcinoma (HCC), with comparative studies reporting longer survival after surgery. We performed a systematic review, meta-analysis, and quantitative bias analysis (QBA) to assess whether residual selection and time-dependent treatment bias could account for the reported benefit.

methodsWe systematically reviewed comparative studies of conversion or salvage hepatectomy versus non-surgical management in initially unresectable HCC and pooled endpoint-specific HRs for OS and PFS/EFS using random-effects models. For each estimate, we extracted the time origin, exposure definition, and adjustment model. Risk of bias and certainty of evidence were assessed using ROBINS-I and GRADE. Robustness to unmeasured confounding, immortal time bias, and small-study effects was evaluated using E-values, tipping-point analysis, probabilistic QBA, timing-bias scenario analyses, and funnel-plot diagnostics.

resultsFourteen studies contributed 24 h: 14 for OS and 10 for PFS/EFS. Hepatectomy was associated with lower hazards of death (HR 0.33, 95% CI 0.22-0.48) and progression or event (HR 0.41, 95% CI 0.28-0.59), although heterogeneity was substantial and both prediction intervals crossed 1.0. E-values suggested robustness to moderate unmeasured confounding, whereas extreme surgical-candidacy confounding attenuated the median bias-adjusted HR to 0.82 for OS and 1.02 for PFS/EFS. Immortal-time bias scenarios did not fully account for the observed associations. OS small-study-effect diagnostics suggested funnel-plot asymmetry, although sample-size-based Peters-type regression was not significant. Certainty of evidence was very low for both endpoints.

conclusionsConversion hepatectomy was associated with better observed survival outcomes in selected patients with initially unresectable HCC after conversion-intent therapy. The association was robust to moderate, but not extreme, assumptions about unmeasured surgical-candidacy confounding. These findings should be interpreted as a composite post-conversion association reflecting surgical clearance, treatment response, favorable tumor biology, and patient selection rather than as the isolated causal effect of hepatectomy. Future studies should report surgical eligibility landmarks, time zero, time to hepatectomy, and reasons for non-resection to clarify the independent contribution of surgery within conversion pathways.

trial registrationPROSPERO CRD420261382843 ( https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=1382843 ).

Indexed as

Carcinoma, HepatocellularHepatectomyLiver NeoplasmsSalvage TherapyHumansPrognosisSurvival RateConversion therapyE-valueHepatectomyHepatocellular carcinomaImmortal-time biasMeta-analysisPublication biasQuantitative bias analysisSurgical oncologySystematic review

Identifiers

PMID42464078
PMCPMC13656502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.